Beijing Med-Pharm Acquires Chinese OTC Drug Manufacturer Sunstone
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Beijing Med-Pharm's acquisition of Chinese OTC drug manufacturer Sunstone Pharmaceutical Co. will help it capitalize on the growing Chinese retail pharmacy space, BMP Chief Financial Officer Fred Powell said in an interview with PharmAsia News
You may also be interested in...
Sanofi Expands China Footprint In OTC And Rx Markets With BMP Sunstone Acquisition
Sanofi-Aventis has gained a leadership position in China's OTC cough/cold market with its $520.6 million acquisition of BMP Sunstone, the latest in the global pharma's parade of consumer health buys
Sanofi Expands China Footprint In OTC And Rx Markets With BMP Sunstone Acquisition
Sanofi-Aventis has gained a leadership position in China's OTC cough/cold market with its $520.6 million acquisition of BMP Sunstone, the latest in the global pharma's parade of consumer health buys
BMP Sunstone Sees Larger Market Share From China Healthcare Reforms, PE Buy Out In The Works?
SHANGHAI - U.S.-listed Chinese pharmaceutical manufacturer and distributor BMP Sunstone reported a 25.8 percent increase in revenue in the second quarter compared to the same year-ago period, for $40.9 million in revenue. The company anticipates gaining market share from China's ongoing healthcare reforms, for which the Chinese government has pledged to invest $124 billion from 2009 to 2011